Pyrexar will be exhibiting at this year's ABS (American Brachytherapy Society) annual meeting in Miami, Florida. The conference held at the Intercontinental Miami hotel, June 13th through the 15th.
This is our first time exhibiting at the conference, and we believe we have a compelling solution to offer. HDR (high dose rate) brachytherapy and hyperthermia share some of the same market challenges. The bottom line is that brachytherapy plus hyperthermia improve cancer patient outcomes.
Like hyperthermia, brachytherapy is a sub-specialty that requires a specific skill set to treat patients. And like hyperthermia, brachytherapy is known to produce increased tumor control without an increase in toxicity. Product planning for hyperthermia is very similar, and the system utilizes the existing brachy catheters placed during HDR.